The UK’s broadest portfolio of doseable cannabis extract vapouriser pens has been launched by Columbia Care.
The products have been manufactured in UK-based manufacturing premises, making Columbia Care the first company to do this. Approved by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the Home Office, Columbia has launched the products under its flagship medical Ceed brand.
Columbia Care CEO, Nicholas Vita, commented: “Columbia Care’s mission has always been to provide patients with access to the highest quality, safest medicinal cannabis products available.
“There are 28 million people suffering from chronic pain in the UK and this range of formulations offers pain doctors the best and most comprehensive selection of cannabinoid treatment options for their patients.
“We are proud to leverage our proprietary IP, formulation expertise, safety surveillance and patient reported data from the US to bring innovation and precision to the growing UK medical cannabis market. We are witnessing increasing numbers of leading doctors integrate the use of medicinal cannabis into their practice evidencing growing acceptance in the UK of the clinical value of cannabinoids.”
The new vaporiser pens are an addition to the company’s initial medical product portfolio, which includes tinctures and solid-fill powder capsules. The four new vapouriser formulations have been selected based on insights from the company’s IMPACT Registry as well as feedback from UK patients, and also offer two different THC:CBD ratios with two different terpene profiles each.
The products will be available for patients throughout the UK when prescribed by a specialist consultant. Columbia says its products offer clinicians and patients in the UK the broadest range of medicinal cannabis products with the capability to target different onset periods and duration of effect.
Columbia Care CSO, Rosemary Mazanet, M.D./Ph.D., added: “UK clinicians practising with cannabis have been telling us that they find cannabis flower difficult to dose, but they recognise the need for fast-onset options for patients experiencing breakthrough pain.
“With the introduction of these vapouriser cartridges, clinicians now have a toolkit of doseable formulations with a range of onset period and duration to help their patients in a similar way to how they use other medicines.
“The vapourisers also have the advantage of being discrete and easy to use which will help many patients who are either cannabis-naïve or who want to continue with their regular daily activities, such as going to work, without the fear of being judged. We are delighted to be able to bring this important line of products to the UK market.”
IPS Pharma will dispense the products directly to patients and it is expected they will be available across a range of the pharmacies which dispense medicinal cannabis prescriptions in the coming weeks.
[activecampaign form=31]
